Binding Modes of Peptidomimetics Designed to Inhibit STAT3

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Dhanik, Ankur ^a   McMurray, John S ^b   Kavraki, Lydia E ^a  

^a Rice University   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDOMIMETIC AGENT; PHOSPHOTYROSINE; PROTEIN SH2; STAT3 PROTEIN;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIMERIZATION; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENTROPY; HUMAN; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE;

CLUSTER ANALYSIS; DRUG DESIGN; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; PEPTIDOMIMETICS; PROTEIN BINDING; PROTEIN CONFORMATION; STAT3 TRANSCRIPTION FACTOR;

EID: 84871207124     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051603     Document Type: Article

References (87)

1. Shay JW, Wright WE, (2002) Telomerase: A target for cancer therapeutics. Cancer Cell 2: 257-265.
2. Isaccs JS, Xu W, Neckers L, (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3: 213-217.
3. Khalil IG, Hill C, (2005) Systems biology for cancer. Current Opinion in Oncology 17: 44-48.
4. Reichert JM, Valge-Archer VE, (2007) Development trends for monoclonal antibody cancer. Nature Reviews Drug Discovery 6: 349-356.
5. Moasser MM, (2007) Targeting the function of the her2 oncogene in human cancer therapeutics. Oncogene 26: 6577-6592.
6. Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, et al. (2008) Design, synthesis, and studies of small molecule stat3 inhibitors. Bioorganic & Medicinal Chemistry Letters 18: 391-395.
7. DiMasi JA, Hansen RW, Grabowski HG, (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics 22: 151-185.
8. Projan SJ, (2007) Why is big pharma getting out of antibacterial drug discovery? Nature Reviews Drug Discovery 6: 115-120.
9. Kamb A, Wee S, Lengauer C, (2007) Why is cancer drug discovery so difficult? Nature Reviews Drug Discovery 6: 115-120.
10. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D, (2011) The cost of drug development: A systematic review. Health Policy 100: 4-17.
11. Anderson AC, (2003) The process of structure-based drug design. Chemistry & Biology 10: 787-797.
12. Kuntz IW, (1992) Structure-based strategies for drug design and discovery. Science 257: 1078-1082.
13. Cavasotto CN, W Orry AJ, (2007) Ligand docking and structure-based virtual screening in drug discovery. Current Topics in Medicinal Chemistry 7: 1006-1014.
14. Matter H, Sotriffer C (2011) Applications and success stories in virtual screening, Wiley-VCH Verlag GmbH & Co. KGaA. 319-358. doi:10.1002/9783527633326.ch12.
15. Xing L, McDonald JJ, Kolodziej SA, Kurumbail RG, Williams JM, et al. (2011) Discovery of potent inhibitors of soluble epoxide hydrolase by combinatorial library design and structure-based virtual screening. Journal of Medicinal Chemistry 54: 1211-1222.
16. Shoichet BK, Kuntz ID, (1991) Protein docking and complementarity. Journal of Molecular Biology 221: 327-346.
17. Kitchen DB, Decornez H, Furr JR, Bajorathe J, (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews Drug Discovery 3: 935-949.
18. Mangoni M, Roccatano D, Di Nola A, (1999) Docking of exible ligands to exible receptors in solution by molecular dynamics simulation. Proteins: Structure, Function, and Bioinformatics 35: 153-162.
19. Karplus M, McCammon A, (2002) Molecular dynamics simulations of biomolecules. Nature Structural Biology 9: 646-652.
20. Terstappen GC, Reggiani A, (2001) In silico research in drug discovery. Trends in Pharmacological Sciences 22: 23-26.
21. Kubinyi H (2006) Success Stories of Computer-Aided Design. Hoboken, NJ: John Wiley & Sons, Inc. 377-424. doi:10.1002/0470037237.ch16.
22. Schneider G, (2010) Virtual screening: an endless staircase? Nature Reviews Drug Discovery 9: 273-276.
23. Coleman DR, Ren Z, Mandal PK, Cameron AG, Dyer GA, et al. (2005) Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. Journal of medicinal chemistry 48: 6661-6670.
24. Mandal PK, Limbrick D, Coleman DR, Dyer GA, Ren Z, et al. (2009) Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription 3: Evaluation and molecular modeling. Journal of medicinal chemistry 52: 2429-2442.
25. Mandal PK, Ren Z, Chen X, Xiong C, McMurray JS, (2009) Structure-affnity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3. Journal of medicinal chemistry 52: 6126-6141.
26. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, et al. (2011) Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. Journal of medicinal chemistry 54: 3549-63.
27. Becker S, Groner B, Müller CW, (1998) Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature 394: 145-51.
28. Bowman T, Garcia R, Turkson J, Jove R, (2000) Stats in oncogenesis. Oncogene 19: 2474-2488.
29. Buettner R, Mora LB, Jove R, (2002) Activated stat signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical Cancer Resesarch 8: 945-954.
30. Hua Y, Jove R, (2004) The stats of cancer-new molecular targets come of age. Nature Reviews Cancer 4: 97-105.
31. Darnell J, Kerr I, Stark G, (1994) Jak-stat pathways and transcriptional activation in response to ifns and other extracellular signaling proteins. Science 264: 1415-1421.
32. Levy DE, Lee C-k, (2002) What does Stat3 do? Journal of Clinical Investigation 109: 1143-1148.
33. Owicki JC, (2000) Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. Journal of Biomolecular Engineering 5: 297-306.
34. García-Nieto R, Pérez C, Gago F, (2000) Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (cox-2). Journal of Computer-Aided Molecular Design 14: 147-160.
35. Okimoto N, Futatsugi N, Fuji H, Suenaga A, Morimoto G, et al. (2009) High-performance drug discovery: Computational screening by combining docking and molecular dynamics simulations. PLoS Computational Biology 5: e1000528.
36. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ, (2009) Chemical probes that competitively and selectively inhibit stat3 activation. PLoS ONE 4: e4783.
37. Kaushik S, Sowdhamini R, (2011) Structural analysis of prolyl oligopeptidases using molecular docking and dynamics: insights into conformational changes and ligand binding. PLoS ONE 6: e26251.
38. Park I, Li C, (2011) Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation. Journal of Molecular Recognition 24: 254-265.
39. Raveh B, London N, Zimmerman L, Schueler-Furman O, (2011) Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinenement of peptides onto their Receptors. PLoS ONE 6: e18934.
40. Kuntz I, (1982) A geometric approach to macromolecule-ligand interactions. Journal of Molecular Biology 161: 269-288.
41. Abagyan R, Totrov M, Kuznetsov D, (1994) ICM-a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. Journal of Computational Chemistry 15: 488-506.
42. Jones G, Willett P, Glen RC, (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. Journal of Molecular Biology 245: 43-53.
43. Rarey M, Kramer B, Lengauer T, Klebe G, (1996) A fast exible docking method using an incremental construction algorithm. Journal of Molecular Biology 261: 470-489.
44. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 19: 1639-1662.
45. Jain AN, (2000) Morphological similarity: a 3D molecular similarity method correlated with proteinligand recognition. Journal of Computer-aided Molecular Design 14: 199-213.
46. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry 47: 1739-1749.
47. Plewczynski D, (2010) VoteDock: consensus docking method for prediction of protein-ligand interactions. Journal of Computational Chemistry 32: 1-14.
48. Trott O, Olson AJ, (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 31: 455-461.
49. Kellenberger E, Rodrigo J, Muller P, Rognan D, (2004) Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins: Structure, Function, and Bioinformatics 57: 225-242.
50. Chang MW, Lindstrom W, Olson AJ, Belew RK, (2007) Analysis of hiv wild-type and mutant structures via in silico docking against diverse ligand libraries. Journal of Chemical Information and Modeling 47: 1258-1262.
51. Onodera K, Satou K, Hirota H, (2007) Evaluations of molecular docking programs for virtual screening. Journal of Chemical Information and Modeling 47: 1609-1618.
52. Rogers JP, Beuscher AE, Flajolet M, McAvoy T, Nairn AC, et al. (2006) Discovery of protein phosphatase 2c inhibitors by virtual screening. Journal of Medicinal Chemistry 49: 1658-1667.
53. Cross JB, Thompson DC, Rai BK, Baber JC, Fan KY, et al. (2009) Comparison of several molecular docking programs: pose prediction and virtual screening accuracy. Journal of Chemical Information and Modeling 49: 1455-1474.
54. Chang MW, Ayeni C, Breuer S, Torbett BE, (2010) Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina. PloS ONE 5: e10926.
55. Li X, Li Y, Cheng T, Liu Z, Wang R, (2010) Evaluation of the performance of four molecular docking programs on a diverse set of protein-ligand complexes. Journal of Computational Chemistry 31: 2109-2125.
56. Li N, Thompson S, Schultz DC, Zhu W, Jiang H, et al. (2010) Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PloS ONE 5: e10126.
57. Plewczynski D, Lziniewski M, Augustyniak R, Ginalski K, (2011) Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database. Journal of Computational Chemistry 32: 742-755.
58. Stahl M, Rarey M, (2001) Detailed analysis of scoring functions for virtual screening. Journal of Medicinal Chemistry 44: 1035-1042.
59. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, et al. (2006) A critical assessment of docking programs and scoring functions. Journal of Medicinal Chemistry 49: 5912-5931.
60. Dhanik A, Kavraki LE (2012) Protein-ligand interactions: computational docking. Hoboken, NJ: John Wiley Sons, Ltd. doi:10.1002/9780470015902.a0004105.pub2.
61. Cavasotto CN, Abagyan RA, (2004) Protein exibility in ligand docking and virtual screening to protein kinases. Journal of Molecular Biology 337: 209-225.
62. Erickson JA, Jalaie M, Robertson DH, Lewis RA, Vieth M, (2004) Lessons in molecular recognition: The effects of ligand and protein exibility on molecular docking accuracy. Journal of Medicinal Chemistry 47: 45-55.
63. Hetényi C, van der Spoel D, (2002) Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Science 11: 1729-1737.
64. Dhanik A, McMurray JS, Kavraki L (2011) On modeling peptidomimetics in complex with the SH2 domain of Stat3. In: Proceedings of 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). New York: IEEE. 3229-3332.
65. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDock-Tools4: automated docking with selective receptor exibility. Journal of Computational Chemistry 30: 2785-2791.
66. Dhanik A, McMurray JS, Kavraki L (2012) AutoDock-based incremental docking protocol to improve docking of large ligands. In: Proceedings of IEEE International Conference on Bioinformatics and Biomedicine Workshops (BIBMW). New York: IEEE. 48-55.
67. Massova I, Kollman P, (2000) Combined molecular mechanical and continuum solvent approach (mm-pbsa/gbsa) to predict ligand binding. Perspectives in Drug Discovery and Design 18: 113-135.
68. Kuhn B, Gerber P, Schulz-Gasch T, Stahl M, (2005) Validation and use of the mm-pbsa approach for drug discovery. Journal of Medicinal Chemistry 48: 4040-4048.
69. McMurray JS, (2007) Structural basis for the binding of high affnity phosphopetides to stat3. Biopolymers 90: 69-79.
70. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Research 28: 235-242.
71. Maestro website. Available: http://www.schrodinger.com/products/14/12/. Accessed 2012 Nov 11.
72. Case DA, Darden TA, Cheatham TE III, Simmerling C, Wang J, et al. (2010) Amber 11. San Francisco, CA: University of California.
73. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general amber force field. Journal of Computational Chemistry 25: 1157-1174.
74. AmberTools website. Available: http://ambermd.org/. Accessed 2012 Nov 11.
75. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR, (1984) Molecular dynamics with coupling to an external bath. The Journal of Chemical Physics 81: 3684-3690.
76. Darden T, York D, Pedersen L, (1993) Particle mesh Ewald: An Nlog(N) method for Ewald sums in large systems. The Journal of Chemical Physics 98: 10089-10092.
77. Wang R, Fang X, Lu Y, Yang CY, Wang S, (2005) The PDBbind database: methodologies and updates. Journal of Medicinal Chemistry 48: 4111-4119.
78. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, et al. (2000) Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Accounts of Chemical Research 33: 889-897.
79. Hartigan JA, Wong MA, (1979) Algorithm as 136: A k-means clustering algorithm. Journal of the Royal Statistical Society Series C (Applied Statistics) 28: 100-108.
80. Weber P, Ohlendorf D, Wendoloski J, Salemme F, (1989) Structural origins of high-affinity biotin binding to streptavidin. Science 243: 85-88.
81. Wade RC, Goodford PJ, (1993) Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. ligand probe groups with the ability to form more than two hydrogen bonds. Journal of Medicinal Chemistry 36: 148-156.
82. Pierce AC, Sandretto KL, Bemis GW, (2002) Kinase inhibitors and the case for CH..O hydrogen bonds in protein-ligand binding. Proteins: Structure, Function, and Bioinformatics 49: 567-576.
83. Panigrahi SK, Desiraju GR, (2007) Strong and weak hydrogen bonds in the protein-ligand interface. Proteins: Structure, Function, and Bioinformatics 67: 128-141.
84. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry 25: 1605-1612.
85. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochemical Pharmacology 22: 3099-3108.
86. Schust J, Berg T, (2004) A high-throughput uorescence polarization assay for signal transducer and activator of transcription 3. Analytical Biochemistry 330: 114-118.
87. Mao X, Ren Z, Parker GN, Sondermann H, Pastorello MA, et al. (2005) Structural bases of unphosphorylated stat1 association and receptor binding. Molecular Cell 17: 761-771.